Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer

Immunotherapies have revolutionized the treatment of a variety of cancers. Epithelial ovarian cancer is the most lethal gynecologic malignancy, and the rate of advanced tumor progression or recurrence is as high as 80%. Current salvage strategies for patients with recurrent ovarian cancer are rarely...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuedi, Cui, Qiulin, Xu, Manman, Liu, Duo, Yao, Shuzhong, Chen, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271774/
https://www.ncbi.nlm.nih.gov/pubmed/35833132
http://dx.doi.org/10.3389/fimmu.2022.901772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271774/
https://www.ncbi.nlm.nih.gov/pubmed/35833132
http://dx.doi.org/10.3389/fimmu.2022.901772

Ejemplares similares